Navigation Links
Fetal Cell Transplant Found To Improve Movement In Patients With Parkinson’s Disease

Latest research shows that fetal cell transplantation for patients with Parkinson’s disease is helping some patients get rid of their medications altogether.//

Parkinson’s disease is a chronic neurological disease that impairs mobility. Patients with Parkinson’s lack the chemical dopamine, which is necessary for movement. Fetal cell transplantation involves transplanting aborted human fetal tissue to replace the lost dopamine-producing cells to help restore movement.

Levodopa (Dopar or Larodopa) is the gold standard treatment for Parkinson’s disease. While the drug offers substantial relief, research shows it tends to lose its effectiveness after five to 10 years of use. Researchers say after one year, the transplant is equivalent to about 30-percent of the levodopa people take. After two years, it’s equivalent to about 50 percent. By the third year, the procedure’s effect is about 60 percent, or two-thirds, the effect of the drug and they say, that it is enough for some people to stop taking their drgs.
'"/>




Page: 1

Related medicine news :

1. Fish Found To Improve Fetal Growth
2. Vitamin Supplements During Pregnancy to Boost Fetal Development
3. Worried About The Sensitive Skin Of Your 2 Year Old? Fetal Skin Cells To Offer Help
4. Using Eyes As The Line Of Reference For Fetal Brain Imaging
5. Simple Eye Movement Test For Early Detection Of Fetal Alcohol Spectrum Disorder
6. Genetic Disorders, Not Fetal Distress Increase Cerebral Palsy Risk
7. Fetal Development Face The Threat By Frequent Ultrasounds
8. New Drug Could Prevent Fetal Alcohol Syndrome
9. Fetal Neural Grafts Improves Motor and Cognitive Function in Huntington Patients
10. Epilepsy Drug Poses High Risk for Fetal Death and Birth Defects
11. Americans Deficient In Dietary Intake Of Choline Needed for Fetal Brain Development
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:10/12/2017)... ... , ... IsoComforter, Inc. ( https://isocomforter.com ), one of the Nation’s ... design of the shoulder pad. The shoulder pad provides optimal support and full ... while using cold therapy. By utilizing ice and water that is circulated from an ...
(Date:10/12/2017)... ... October 12, 2017 , ... Information about ... intend to develop to enable prevention of a major side effect of chemotherapy ... especially in pediatric patients. For cisplatin, hearing loss is FDA listed on-label as ...
(Date:10/12/2017)... ... October 12, 2017 , ... Leading pediatric oncology experts at ... for the 49th Congress of the International Society of Paediatric Oncology (SIOP) ... Center for Cancer and Blood Disorders at Children’s National, and Stephen P. ...
(Date:10/12/2017)... ... ... Health Literacy Innovations (HLI), creator of the Health Literacy ... Patient Education Network (CPEN), an independent professional organization that shares best practices in ... , As CPEN’s strategic partner, HLI will help support CPEN members by sharing ...
(Date:10/12/2017)... D.C. (PRWEB) , ... October 12, 2017 , ... ... Cal Dining at the University of California Berkeley, and other leading institutions in ... the buying power of institutions to change the way animals are raised for ...
Breaking Medicine News(10 mins):
(Date:9/27/2017)... and NEW YORK , Sept. 27, 2017  DarioHealth ... and big data solutions, today announced that its MyDario product is expected ... local TV listings for when The Dr. Oz Show airs in your ... The nine-time Emmy ... ...
(Date:9/23/2017)... Sept. 22, 2017 Janssen Biotech, Inc. (Janssen) ... letter from the U.S. Food and Drug Administration (FDA) ... sirukumab for the treatment of moderately to severely active ... clinical data are needed to further evaluate the safety ... active RA. ...
(Date:9/19/2017)... 19, 2017 HistoSonics, Inc., a venture-backed medical device company developing a non-invasive, robotically ... announced three leadership team developments today:   ... ... Tom ... Veteran medical device executive Josh Stopek , PhD, who ...
Breaking Medicine Technology: